Edition:
United Kingdom

Infinity Pharmaceuticals Inc (INFI.OQ)

INFI.OQ on NASDAQ Stock Exchange Global Select Market

1.86USD
16 Feb 2018
Change (% chg)

-- (--)
Prev Close
$1.86
Open
--
Day's High
--
Day's Low
--
Volume
--
Avg. Vol
380,135
52-wk High
$3.84
52-wk Low
$0.93

Chart for

About

Infinity Pharmaceuticals, Inc. is a biopharmaceutical company. The Company is engaged in the discovery, development and delivery of medicines to treat diseases. The Company develops small molecule drugs that target disease pathways for potential applications in oncology. Its product candidate is duvelisib, also known as IPI-145,... (more)

Overall

Beta: 2.69
Market Cap(Mil.): $80.60
Shares Outstanding(Mil.): 50.69
Dividend: --
Yield (%): --

Financials

  Industry Sector
P/E (TTM): -- 83.93 16.64
EPS (TTM): -- -- --
ROI: -- 1.66 10.66
ROE: -- 2.58 14.30

BRIEF-Infinity Expects Net Loss For 2018 To Range From $40 Mln To $50 Mln​

* INFINITY PHARMACEUTICALS INC - ‍INFINITY EXPECTS NET LOSS FOR 2018 TO RANGE FROM $40 MILLION TO $50 MILLION​

08 Jan 2018

BRIEF-Infinity Q3 loss per share $0.14

* Infinity provides company update and reports third quarter 2017 financial results

07 Nov 2017

BRIEF-Verastem makes milestone payment to Infinity Pharmaceuticals

* Verastem pays milestone payment to Infinity Pharmaceuticals

17 Oct 2017

BRIEF-Infinity Pharmaceuticals and Bristol-Myers Squibb expand clinical collaboration

* Infinity Pharmaceuticals and Bristol-Myers Squibb expand clinical collaboration evaluating ipi-549 in combination with Opdivo (nivolumab)

25 Sep 2017

Earnings vs. Estimates